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Abstract
Objectives: To assess the safety and efficacy of rapamycin in treating children with vascular tumours
and malformations.
Study design: We performed a retrospective review at a large tertiary care paediatric centre to assess the efficacy and safety of using rapamycin to treat vascular tumours and malformations. Response
to therapy was defined by patient-reported symptom improvement, radiological reduction in size of
lesions, and/or improvement of laboratory parameters.
Results: Forty-two patients (7 with vascular tumours and 35 with vascular malformations) have been
treated with rapamycin. Despite 33 of 42 patients being diagnosed in the first year of life, the median
age of initiating rapamycin was 11 years. Of the 38 children treated for a minimum of 4 months, 29
(76%) exhibited a clinical response. Twenty-one patients had follow-up imaging studies and of these,
16 (76%) had radiographic decrease in lesion size. Median time to demonstration of response was
49 days. All five children with vascular tumours and all three children with vascular malformations
under the age of 4 years showed a clinical response. Response rate was lower for children ≥ 4 years of
age (0/2, 0% for vascular tumours; 21/28, 75% for vascular malformations). No patient experienced
an infection directly related to rapamycin or discontinued rapamycin due to toxicity.
Conclusions: Rapamycin is safe and efficacious in most children with select vascular tumours and
malformations. Young children appear to respond better, suggesting that early initiation of rapamycin
should be considered.
Keywords: Rapamycin; Sirolimus; Vascular malformation; Vascular tumour

Vascular anomalies (VAs) are a heterogeneous group of
disorders that are characterized according to the classification
system of the International Society for the Study of Vascular
Anomalies (ISSVA) (1). These are broadly divided into vascular tumours, which are proliferative lesions, and vascular

malformations, which are thought of as being nonproliferative
anomalies of vascular channel morphogenesis and may be associated with overgrowth.
VAs may cause significant morbidity: growth of lesions can
result in external compression of vital structures and organ

Received: January 26, 2019; Accepted: April 1, 2019
© The Author(s) 2019. Published by Oxford University Press on behalf of the Canadian Paediatric Society. All rights reserved.
For permissions, please e-mail: journals.permissions@oup.com

e25

e26
dysfunction, and may be associated with significant acute and
chronic pain, coagulopathy, bleeding, or thrombosis (2,3). In
addition, depending on their location, patients may experience
psychological trauma from disfiguring lesions (4). Conventional
therapies for vascular malformations have focused on relieving
symptoms by a combination of methods, including interventional approaches such as sclerotherapy and laser ablation, as well
as surgical debulking. However, the infiltrative pattern of many
lesions prevents their complete excision. Similarly, while sclerotherapy is suitable for improving pain in many patients with vascular malformations, it is not always possible, is noncurative, and
requires multiple treatments. In contrast, vascular tumours have
been managed medically with corticosteroids, interferon, antiangiogenic therapies such as bevacizumab, and chemotherapeutic
agents such as vincristine (5). However, these medical therapies
are not without significant toxicities.
In 2011, the first report on the use of rapamycin in the treatment
of five children with vascular tumours and one child with a vascular malformation led to the realization that perhaps a medication with significantly less toxicity could now be used for children
with vascular tumours (6). Most importantly, it was suggested
that perhaps vascular malformations could also be treated medically, thereby offering such patients a new, previously unavailable form of therapy. Over the next several years, an increasing
number of case reports emerged demonstrating the effectiveness
of rapamycin in a variety of vascular tumours and malformations
(7). Finally, in 2016, Adams et al. reported the first prospective
(phase 2) study which demonstrated that rapamycin was safe and
efficacious in patients with complex VAs (8).
Rapamycin is an inhibitor of the mammalian target of rapamycin complex (mTOR). mTOR is a serine and threonine
kinase that functions as a key regulator of cellular growth and
metabolism by integrating both intracellular and extracellular signals. The mTOR pathway consists of several signalling
proteins (e.g., PI3K, AKT), and its activation has been associated with angiogenesis and lymphangiogenesis (9,10). Various
mutations that impact the mTOR pathway have been identified
in a number of VAs: TIE2 mutations in 50% of common venous malformations, AKT mutations in Proteus syndrome,
and P13K mutations in both isolated and syndromic lymphatic
malformations such as CLOVES syndrome (11,12,13).
The Hospital for Sick Children in Toronto is the largest tertiary care paediatric centre in Canada. It follows over 600
children with complex vascular tumours and malformations.
Over the last 6 to 7 years, an increasing number of such children
have been treated with rapamycin. Herein, we present our
considerable and rapidly growing experience in treating such
children using rapamycin.

METHODS
A single-centre retrospective cohort study was performed on
children with VAs who were treated with rapamycin between
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February 2012 and December 2018. All patients treated at The
Hospital for Sick Children, Toronto were included. Patients
were diagnosed as having VAs based on clinical and imaging
findings, with 17 having confirmed pathologic examination. The
primary outcome measure was response to therapy (described
below). Institutional review board approval was obtained prior
to conducting this study.
Rapamycin was initiated at 0.8 mg/m2 per dose administered
twice daily or 2.5 mg/m2 administered once daily in children
above the age of 5 years, with subsequent dose adjustments made
to target a trough level between 5 and 15 ng/mL. Laboratory
parameters including, but not limited to, a complete blood
count, differential, liver and renal function, lipid profile, fibrinogen, and d-dimer were monitored. Response to therapy was defined as patient-reported improvement of symptoms (e.g., pain),
clinical or radiological reduction in the size of the lesion, and/or
improvement of laboratory parameters (e.g., d-dimer, platelets,
hemoglobin [in cases where patients were bleeding secondary to
their vascular malformation], or albumin [in cases where patients
exhibited protein losing enteropathy]). Follow-up imaging
studies were obtained after a minimum of 6 months on therapy,
or as clinically indicated. Patients were treated for a minimum
of 4 months before assessing clinical response. Patients who had
a response were treated with therapeutic dose rapamycin for a
minimum of 12 months prior to tapering. Demographic and
clinical data are summarized descriptively.

RESULTS
Patient characteristics
Forty-two patients with VAs were treated with rapamycin.
Thirty-eight of these 42 patients were treated for a minimum of
4 months; these 38 patients were included in the final analysis.
Most patients were diagnosed at birth with their VA: median
age of diagnosis was birth (range: 0 to 11 years). However,
median age at initiation of rapamycin therapy was 10 years of
age (range: 0 to 17.5 years). Median follow-up was 22 months
(range: 4 to 80 months).
Of the 38 patients included in the analysis, 7 had vascular
tumours (5 with kaposiform hemangioendothelioma, 1 with a
diffuse transmural infantile hemangioma in the GI tract, and 1
with a biopsy-proven infantile hemangioma of the face that grew
in adolescence) and 31 had vascular malformations (Tables 1
and 2). Among the 31 patients with vascular malformations,
there were 2 patients with Klippel-Trenaunay syndrome, 1
with Blue Rubber Bleb Nevus (BRBNS) syndrome, and 1
with a fibroadipose vascular malformation (FAVA). Apart
from cosmetic concerns all patients were symptomatic; pain
was the most common symptom in patients with vascular
malformations. Other indications for initiating therapy with
rapamycin included recurrent cellulitis (two patients), stridor
or airway compromise (seven patients), protein-losing enteropathy (two patients), gastrointestinal bleeding (two patients),
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Table 1. Diagnoses and disease response in patients treated for a minimum of 4 months

Diagnosis
Vascular Tumours
Kaposiform Hemagioendothelioma
Other
Vascular Malformations
Lymphatic (includes one pt with intestinal
lymphangiectasia)
Mixed (five LVM, three CLVM)
Venous (includes one pt with BRBN)
Capillary (Phakomatosis pigmento vascularis)
Fibro-adipose vascular anomaly
Total

N

Clinical
response (N)

Median time to
response (d)

Remain on
rapamycin (N)

5
2

4 (80%)
1 (50%)

46
56

2
1

15

11 (73%)

49

12

8
6
1
1
38

7 (87%)
5 (83%)
0 (0%)
1 (100%)
29 (76%)

42
63
n/a
98
49

8
5
0
1
29

BRBN Blue rubber bleb nevus syndrome; CLVM Capillary-lymphatic-venous malformation; LVM Lymphatic-venous malformation.

pleural/pericardial effusions (two patients), and orbital mass
with risk to vision (two patients).

Prior therapy
Most patients had received other therapies prior to initiating rapamycin. All patients with vascular tumours had received either
steroids, vincristine, beta-blockers, or a combination thereof. Two
patients, one with a large venous malformation, and another with
a combined slow-flow malformation (venous and lymphatic)
had received low molecular weight heparin for localized intravascular coagulopathy (LIC). Thirteen patients had undergone
surgical procedures: 11 had undergone debulking surgeries, one
had insertion of a titanium rod for recurrent fractures because of
a vascular malformation (LVM) involving his femur, and another
underwent obliteration of his right middle ear because of a persistent cerebrospinal fluid (CSF) leak causing recurrent meningitis. Sixteen patients underwent sclerotherapy either prior to or
concurrently with rapamycin therapy.

Response
Twenty-nine out of 38 children (76%) showed a clinical response based on a decrease in mass size or pain (25 patients;
as judged by the patient/family) or a decrease/cessation of gastrointestinal blood loss (2 patients), protein losing enteropathy
(1 patient), and/or pleural/pericardial effusions (1 p atient).
Median time to demonstration of a response was 49 days (range:
12 to 134 days). Clinical response rates were similar across
diagnoses (Table 1 and Figure 1). Of note, all eight children
(five vascular tumours and three vascular malformations) under
4 years of age showed a clinical response. None of the patients
had frankly progressive disease.
Of the 21 children with follow-up imaging (20 MRIs, 1
ultrasound), 16 (76%) showed a decrease in lesion size.

Figure 1. Photograph and MRI of lymphatic malformation of the tongue
before and after 3 years on rapamycin. Permission to publish these
photographs was provided by the patient’s parents. This is patient #17 in
Table 2.

Twenty-four children had abnormalities in baseline blood
work; of these, 17 (71%) showed improvement, including normalization of d-dimers (10), improvements in hemoglobin
(11), platelet count (1), gamma globulin levels (1), albumin
(1), or fibrinogen (1).
Median duration of treatment was 12 months (range: 4 to
45 months) with median follow-up of 22 months (range: 4 to
80 months). Of the 29 patients who responded to rapamycin
5 were weaned off rapamycin after a good response; 3 of these
had a recurrence of clinical symptoms and were re-started
on rapamycin. Upon restarting rapamycin, all three patients
again showed a clinical response with improvement of pain
and decrease in lesion size. One of these three patients (with
kaposiform hemangioendothelioma [KHE]) discontinued
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Table 2. Patient characteristics and response to rapamycin. Patients are grouped by diagnoses and then by ascending age

Pt

Diagnosis

Age at
initiation

Prior therapy

Response to Rapamycin

Vascular tumours
Kaposiform Hemagioendothelioma
1
KHE
Neck and thorax

1m

Corticosteroids

2
3

KHE
KHE

Face and neck
Lower extremity

3m
1y8m

Propranolol
Propranolol

4

KHE

Lower extremity

2y9m

5

KHE

Lower extremity

15 y 1 m

Corticosteroids and
vincristine
Corticosteroids

Modest reduction in bulk, resolution of
pleural and pericardial effusions, normalization of platelet count
Modest reduction in bulk
Moderate reduction in bulk, normalization of d-dimer
Modest reduction in bulk, decreased
pain, improvement of d-dimer
No response

Other tumours
6
Diffuse
hemangiomas

Face, neck,
abdomen

3y3m

7

Neck, airway

10 y

Infantile hemangioma

Location

Red cell transfusions;
Corticosteroids and
vincristine
Corticosteroids,
vincristine, nadolol,
laser

Resolution of GI bleeding, normalization of Hb and ferritin

Significant reduction of bulk, resolution
of stridor
Significant reduction of bulk

Vascular malformations
Lymphatic Malformations
8
LM – microcystic Face and neck

1m

Nil

9

2m

Sclerotherapy

10

LM – mixed cystic Upper extremity,
neck
LM – mixed cystic Face, neck, airway

4y1m

11

LM – microcystic

4y2m

12

GI tract, abdomen,
pelvis
LM – mixed cystic Face, neck, airway

Tracheostomy, sclerotherapy
Nil

13

LM – mixed cystic Face and neck

6y

14

7y7m

15
16

LM – mixed cystic Upper extremity,
neck and thorax
LM – mixed cystic Face and neck
LM – mixed cystic Retroperitoneum

17

LM – microcystic

14 y

18

LM – microcystic

19
20

LM – microcystic
LM – microcystic

GI tract,
retroperitoneum
Pelvis and lower
extremity
Lower extremity
Orbit

4y6m

8y9m
13 y 1 m

14 y 9 m

14 y 11 m
16 y 9 m

Partial resection,
tracheostomy,
sclerotherapy
Tracheostomy,
sclerotherapy
Multiple resections,
sclerotherapy
Partial resection
Two partial resections
Nil (repeated infusions
of albumin)
Propranolol, partial
resection,
sclerotherapy
Nil
Nil

No response

No response
No response
Significant reduction of bulk, improvement of d-dimer
Modest reduction in bulk, marked
improvement in ability to cap
tracheostomy
No response
Modest reduction of bulk
Significant reduction of bulk, improvement of pain and d-dimer
Resolution of protein-losing enteropathy
and edema
Marked improvement of pain and ambulation
Significant reduction of bulk
Modest reduction in bulk
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Table 2. Continued

Pt

Diagnosis

Location

Age at
initiation

Prior therapy

Response to Rapamycin

21

LM – microcystic

Upper extremity

17 y 6 m

Sclerotherapy, skin debridement

22

LM – possible GLA Head, neck, thorax,
abdomen

4y2m

Surgical correction of
CSF leak

Modest reduction of bulk, significant
improvement of pain and reduced
bleeding
No response

Combined Malformations
23
LVM
24
LVM

Thorax
Orbit

1 year
4y3m

25

LVM

Face and neck

5y7m

Sclerotherapy
Partial resection, sclerotherapy
Nil

26

LVM

Upper extremity

10 y 9 m

Partial resection

27

LVM (primarily
venous)
CLVM + overgrowth = KTS

Lower extremity

14 y 10 m

Reduction of fractures,
osteotomy, LMWH
Topical beta blocker

28

29

30

Upper extremity
with overgrowth, hepatic,
intraspinal
CLVM + overLower extremity
growth = KTS
with overgrowth,
pelvis
CLM + overgrowth Thorax,
retroperitoneum,
pelvis

Venous Malformations
31
VM

Face and neck

32

VM

Face and neck

33

VM

Lower extremity

34

VM

35

VM

36

VM - BRBNS

Tongue, oropharynx
Upper extremity
and thorax
GI tract and skin

Capillary malformations
37
PPV
Other malformations
38
FAVA

8y9m

11 y 10 m

Multiple resections,
venous embolization

14 y 10 m

Sclerotherapy

12 y
Nil
1 month
13 y
Tracheostomy, Sclerotherapy
16 y 6 m
Sclerotherapy

Modest reduction in bulk
Marked reduction in bulk and proptosis
Significant reduction of bulk, improvement of d-dimer
Significant reduction of bulk, resolution
of recurrent cellulitis
Marked improvement of pain, resolution
of LIC
Modest improvement of bulk, improvement of d-dimer

Moderate reduction in bulk of cutaneous
lesions, marked improvement of pain,
normalization of d-dimer
No response

Modest reduction of bulk, improvement
of d-dimer
No response

17 y 1 m

Corticosteroids

17 y 9 m

LMWH, Sclerotherapy

15 y 8 m

Red cell transfusions,
surgical resection

Marked improvement of pain and ambulation, improvement of d-dimer
Marked improvement of pain and resolution of opioid use
Marked improvement of pain and range
of motion, modest reduction in bulk
Moderate reduction in bulk of cutaneous
lesions, normalization of Hb

Lower extremities
and GI tract

16 y

Red cell transfusions

No response

Lower extremity

15 y 6 m

Sclerotherapy

Marked improvement of pain and ambulation, moderate reduction of bulk

BRBN Blue rubber bleb nevus syndrome; CLVM Capillary-lymphatic-venous malformation; FAVA Fibro-adipose vascular anomaly; Hb Hemoglobin; KHE Kaposiform hemangioendothelioma; KTS Klippel-Trenauny syndrome; LIC Localized intravascular coagulation; LM Lymphatic
malformation; LVM Lymphatic-venous malformation; VM Venous malformation; PPV Phakomatosis pigmento vascularis.
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and then re-started therapy a total of three times, with an excellent response seen each time. Two patients remain off rapamycin while 27 remain on rapamycin.

Safety
Overall, rapamycin was very well tolerated, and toxicities were
consistent with previously reported side-effects. Twentynine (76%) had mild hypertriglyceridemia, and no patients
required statin therapy. In 20 patients (52%), mouth sores were
reported without need for therapy discontinuation. Infectious
complications included the following: culture-negative sepsis while
travelling in South Asia (1), recurrence of pre-existing Clostridium
difficile colitis (1), serum sickness secondary to antibiotic use to
treat an acute otitis media and subsequent pneumonia (1), recurrent meningitis secondary to a CSF leak from a temporal bone defect (1). In each case, the patient was treated for the infection and
remained on rapamycin with no interruption except in one case
(case of sepsis) where rapamycin was interrupted for 2 months.

DISCUSSION
To the best of our knowledge, this retrospective cohort review
constitutes the largest Canadian experience in treating children with
VAs using rapamycin. We demonstrate that rapamycin is an efficacious and well-tolerated therapy for children with VAs, including
patients who have not responded to treatment with other modalities.
This was noted as improvements in pain, reduction in lesion bulk,
and improvement of associated complications such as LIC, as evidence by the d-dimer, as well as reduced bleeding and protein losses
from gastrointestinal VA. These findings are compatible with other
reported case series (6,8,14–16). Of note, rapamycin was effective
in both vascular tumours and malformations, and in a variety of
anatomic locations. The success of rapamycin in treating different
lesion types may stem from the critical role of mTOR in integrating
multiple signalling pathways, including PI3K and TIE2, which are
important for cellular proliferation (11,17).
In some patients, the effect of rapamycin was dramatic and
life changing. Examples of this include two patients who had recurrent gastrointestinal bleeding (patients #6 and #36 in Table
2). Both patients were receiving monthly red cell transfusions
and had undergone unsuccessful intestinal resections to reduce
their GI bleeding. Shortly after commencing rapamycin, these
patients became transfusion independent. Similarly, one patient
(patient #17 in Table 2) with a diffuse GI lymphatic malformation had a severe protein losing enteropathy and debilitating
edema for over 10 years leading to numerous hospitalizations
and albumin infusions. At the time of initiating rapamycin, her
serum albumin was 9 g/L (normal: 32 to 52 g/L) and her serum
IgG was 2.4 g/L (normal: 6.6 to 15.3 g/L). Within 6 months
of starting rapamycin both values had normalized, and have
remained so after 3 years. These cases suggest that the use of
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rapamycin may enable avoidance of hospitalizations and invasive procedures associated with significant morbidity.
Unsurprisingly, given the responses seen, most patients
reported here remain on rapamycin. After a period of disease
stability, several patients have weaned off therapy and, in five
cases, discontinued therapy. In three cases, due to regrowth of
the lesion (KHE) or recurrence of bleeding (diffuse hemangioma of the GI tract and blue rubber bleb nevus syndrome),
they have restarted rapamycin and had a good response again.
Our experience suggests that most patients may need to remain
on rapamycin for long periods of time, although they may remain on very low doses.
There were no major toxicities directly attributable to rapamycin. The rate of mouth sores seen in our study (52%) was
notably higher than the reported 17% by Adams et al. (8). It
is possible that our use of once daily dosing led to higher peak
serum rapamycin levels and/or higher local concentrations in
patients taking liquid rapamycin. Nevertheless, dose reduction
was only required in three patients. In addition, we began to
prescribe a lidocaine-based mouth wash or a triamcinolonelidocaine oral gel (Oracort, Taro Pharmaceuticals, NY) which
helped mitigate pain associated with mouth sores.
The rate of hypercholesterolemia/hypertriglyceridemia was
very high (74%) and is explained by the fact that most samples
were drawn without asking children to be strictly fasting.
Importantly, elevations were mild, and there were no patients
who required statin therapy. While the short-term elevation of
cholesterol/triglycerides may be of little clinical consequence
in children, the potential need for prolonged therapy and the
use of rapamycin in adults with concurrent cardiovascular risk
factors warrants consideration.
Four infectious complications were noted, none of which could
be directly attributed to rapamycin. Of note, one child experienced
recurrent meningitis but was found to have a CSF leak secondary
to a petrous bony defect. Recently, two cases of pneumocystis jiroveci
pneumonia (PJP) presenting in neonates on rapamycin but heavily
pretreated with steroids were reported, highlighting the need for
PJP prophylaxis in very young children (18).
We noticed an association between the patient’s age at
initiating rapamycin and their likelihood to respond. Of
the patients with vascular tumours, all five patients under
the age of 4 years (four KHE, one diffuse hemangiomas)
responded to rapamycin, while the two older patients did
not (Figure 2A). Similarly, for vascular malformations, all
three patients under the age of 4 years (100%) responded to
rapamycin as compared to 75% (21 of 28) of patients above
the age of 4 years (Figure 2B). It is possible that our use of
twice daily dosing in younger patients led to steadier drug
levels, and thus an improved response as compared to older
patients. However, all patients had doses adjusted to have
trough levels between 5 and 15 ng/mL. There may be many
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Figure 2. Response to rapamycin by age for vascular tumours (A) and vascular malformations (B).

possible factors that contribute to a decreased response
in older children, including physiologic maturation of the
lymphatic system over time. Older children are more likely
to have tried other therapies and may have scarring of the
VA, either from sclerotherapy, surgery, or prior infections
of the VA as can occur in cystic lymphatic malformations
(LMs); such scarring is probably not likely to respond to
medical therapy. An association between age and response
to rapamycin has been suggested but is yet to be proven in a
prospective study (8,19).
The two largest published cohorts of patients treated with rapamycin have shown that patients with KHE and LMs, particularly
those with a microcystic lymphatic component, appear the most
likely to respond (8,20). As a result, 28 of 38 patients referred to us
had either KHE or a vascular malformation with a lymphatic component (Table 1). Our experience mirrors that of the aforementioned studies, with 22 of 28 (79%) of these patients responding
to rapamycin. We add to this literature our observation that young
children with VA appear to respond better to rapamycin. This success has resulted in an increasing number of referrals for patients
with VA seeking medical therapies; 11 of this cohort were referred
in 2018 with an additional 5 patients (not captured here) being referred at the time of data collection.
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Limitations of the study include its retrospective nature,
and the fact that many patients received pre or concurrent
sclerotherapy, making it challenging to accurately access
the effect of rapamycin alone. Finally, pain is a notable
feature of the morbidity suffered by patients but is challenging to assess in a retrospective study. Improvements in
pain noted in Table 2 reflect objective decrease in analgesic
use. Currently, a quality of life survey is being implemented
in the clinic to improve global assessment of response to
rapamycin.
The success of rapamycin in treating patients with
selected vascular tumours and malformations does not detract from other modalities used to treat VAs. Indeed, several patients in our cohort received sclerotherapy with good
effect. Similarly, there are case reports of complete surgical
excision in otherwise inoperable VAs being facilitated by
first using rapamycin to shrink the lesion (4). As such, rapamycin may be perceived in some cases as an adjunct to
interventional or surgical therapy, while in others it may be
the primary therapeutic modality.
In summary, our results suggest that rapamycin is safe
and efficacious to treat children and adolescents with
selected vascular anomalies. We note an association
between younger age and response to rapamycin. This
highlights the importance for community practitioners
to recognize VAs and make early referrals. Several
questions regarding the use of mTOR inhibition in VAs
remain, including clearly defining which lesions respond
best, duration of therapy, long-term complications, and
the role of other rapalogs such as everolimus. Further
cooperative prospective trials and are needed to answer
these questions.
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